Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HER3-ADC1
- Development stage
- Preclinical
- Lead developer
- Elevation Oncology
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
HER3-ADC1 is an antibody-drug conjugate (ADC) designed to target human epidermal growth factor receptor 3 (HER3) expressing cancers. It comprises the human HER3 monoclonal antibody seribantumab, conjugated via a cleavable valine-citrulline linker to the cytotoxic payload monomethyl auristatin E (MMAE) using a stochastic cysteine conjugation method. This ADC has demonstrated target-dependent in vitro cytotoxicity and in vivo anti-tumor activity in HER3-expressing pancreatic cancer patient-derived xenograft models. Developed by Elevation Oncology, HER3-ADC1 aims to selectively deliver a potent chemotherapy agent to cancer cells, thereby minimizing systemic toxicity.
02
Targets
TUBB (Tubulin (alpha and beta subunits))ERBB3 (Erb-b2 receptor tyrosine kinase 3)
Beyond the preview
Go deeper on HER3-ADC1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HER3-ADC1.